Registration Dossier

Data platform availability banner - registered substances factsheets

Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.

The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.

Diss Factsheets

Toxicological information

Sensitisation data (human)

Currently viewing:

Administrative data

Endpoint:
sensitisation data (humans)
Type of information:
other: Case report
Adequacy of study:
supporting study
Reliability:
2 (reliable with restrictions)
Rationale for reliability incl. deficiencies:
other: Human case study. Limitations in design and/or reporting but otherwise adequate for assessment.

Data source

Reference
Reference Type:
publication
Title:
Short Communication: Contact sensitivity and systemic reaction to pseudoephedrine and lignocaine
Author:
Downs; A.M.R.
Year:
1998
Bibliographic source:
Contact Dermatitis, 1998, 39, 33

Materials and methods

Type of sensitisation studied:
skin
Study type:
case report
Test guideline
Qualifier:
no guideline followed
Principles of method if other than guideline:
A case report of a 35-year-old atopic woman after possible sensitization to prilocaine and lignocaine leading to the sensitization to pseudoephedrine due to cross-sensitization.
GLP compliance:
no

Test material

Constituent 1
Reference substance name:
Pseudoephedrine hydrochloride
EC Number:
206-462-1
EC Name:
Pseudoephedrine hydrochloride
Cas Number:
345-78-8
IUPAC Name:
2-(methylamino)-1-phenylpropan-1-ol hydrochloride
Details on test material:
- Name of test material (as cited in study report): pseudoephedrine

Method

Type of population:
general
Ethical approval:
not applicable
Subjects:
- Number of subjects exposed: 1
- Sex: Female
- Age: 35
Clinical history:
A 35-year-old atopic woman applied Emla cream (lignocaine 2.5%, prilocaine 2.5%) to inflamed skin after a sunburn. Within a few days, she developed blistering of the skin. Several months later, she took a tablet of Nurofen Cold and Flu Remedy (200 mg ibuprofen, 30 mg pseudoephedrine HCl), which after several hours induced palpitations and a generalised red itchy eruption. Prednisolone 30 mg oral daily controlled the cutaneous reaction within a week. She re-challenged herself with oral Nurofen without incident, but Nurofen Cold and Flu Remedy produced the same symptoms, which again settled with a short course of oral prednisolone. Several weeks later, she was given a 2% plain lignocaine intrabuccal injection. Within minutes, she developed swollen hands, tachycardia and a red itchy eruption over her trunk and limbs. To her knowledge, she had never had a previous local anaesthetic administered. She was taking no other medication.
Route of administration:
dermal
Details on study design:
Patch testing with: pseudoephedrine (1% pet.), lignocaine (1% pet.), prilocaine (1% pet.) procaine, amylocaine and the European standard series.

Results and discussion

Results of examinations:
Patch testing showed positive reactions (++) to pseudoephedrine 1% pet. and lignocaine 1% pet. at 2 and 4 days, a positive reaction (+) to prilocaine 1% pet. at D4, but negative reactions to procaine, amylocaine and the European standard series. Sensitization to prilocaine and lignocaine may have occurred in this patient following the topical application of Emla cream to an already inflamed skin site. The presence of a benzene ring and a distally-placed nitrogen molecule, surrounded by methyl groups, in lignocaine, prilocaine and pseudoephedrine, suggests some sharing of epitopes between all 3 chemicals. Therefore, sensitization to pseudoephedrine may be due to crosssensitization.

Applicant's summary and conclusion

Conclusions:
Sensitization to pseudoephedrine may be due to crosssensitization after possible sensitization to prilocaine and/or lignocaine following the topical application of these substances in Emla cream.
Executive summary:

In a case report sensitization to prilocaine and lignocaine may have occurred in a patient following the topical application of Emla cream to an already inflamed skin site. Several months later application of pseudoephidrine resulted in palpitations and a generalised red itchy eruption. Patch testing showed positive reactions to pseudoephedrine, lignocaine and prilocaine. The presence of a benzene ring and a distally-placed nitrogen molecule, surrounded by methyl groups, in lignocaine, prilocaine and pseudoephedrine, suggests some sharing of epitopes between all 3 chemicals. Therefore, sensitization to pseudoephedrine may be due to crosssensitization.